Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • Luis Martinez-LostaoEmail author
  • Diego de Miguel
  • Alberto Anel
  • Javier Naval
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_2


Historical Background

Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) was independently identified by two different groups as the third member of the tumor necrosis factor (TNF) super-family (Wiley et al. 1995; Pitti et al. 1996). It was soon described as capable of inducing apoptosis in transformed cells while sparing normal cells (LeBlanc and Ashkenazi 2003). Apo2L/TRAIL is a type-II membrane protein, composed of 281 amino acids and its gene, designated as TNFSF10, is located on human chromosome 3 at locus 3q26. Its C-terminal extracellular domain shares significant homology with other members of the TNF super-family, whereas the N-terminal does not. The polypeptide moiety of the Apo2L/TRAIL monomer has a predicted molecular mass of 32.5 kDa, but its mature, fully glycosylated form has a molecular mass of around...

This is a preview of subscription content, log in to check access.


  1. Anel A, Bosque A, Naval J, Pineiro A, Larrad L, Alava MA, et al. Apo2L/TRAIL and immune regulation. Front Biosci. 2007;12:2074–84.PubMedCrossRefGoogle Scholar
  2. Azijli K, Weyhenmeyer B, Peters GJ, de Jong S, Kruyt FA. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ. 2013;20:858–68.  https://doi.org/10.31038/cdd.2013.28.CrossRefPubMedPubMedCentralGoogle Scholar
  3. de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L. Onto better TRAILs for cancer treatment. Cell Death Differ. 2016;4:174.Google Scholar
  4. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010.Google Scholar
  5. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther. 2012;11:3–13.  https://doi.org/10.1158/1535-7163.MCT-11-0434.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 2009;137:721–35.  https://doi.org/10.1016/j.cell.2009.03.015.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, Van Herreweghe F, et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ. 2012;19:2003–14.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Kantari C, Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta. 2011;1813:558–63.  https://doi.org/10.1016/j.bbamcr.2011.01.026.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice. Nat Immunol. 2003;4:255–60.PubMedCrossRefGoogle Scholar
  10. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66–75.  https://doi.org/10.1038/sj.cdd.4401187.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006;26:7046–55.  https://doi.org/10.1128/mcb.00520-06.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Ozoren N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia. 2002;4:551–7.  https://doi.org/10.1038/sj.neo.7900270.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687–90.  https://doi.org/10.1074/jbc.271.22.12687.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000;12:599–609.  https://doi.org/10.1016/s1074-7613(00)80211-3.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001;7:94–100.PubMedCrossRefGoogle Scholar
  16. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005;280:40599–608.  https://doi.org/10.1074/jbc.M509560200.CrossRefPubMedPubMedCentralGoogle Scholar
  17. von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell. 2015;27:561–73.CrossRefGoogle Scholar
  18. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007;13:1070–7. http://www.nature.com/nm/journal/v13/n9/suppinfo/nm1627_S1.htmPubMedCrossRefGoogle Scholar
  19. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang C-P, JK N, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–82.PubMedCrossRefGoogle Scholar
  20. Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol. 2005;175:5586–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Luis Martinez-Lostao
    • 1
    Email author
  • Diego de Miguel
    • 2
  • Alberto Anel
    • 2
  • Javier Naval
    • 2
  1. 1.Servicio de InmunologíaHospital Clínico Universitario Lozano BlesaZaragozaSpain
  2. 2.Departamento de Bioquímica, Biología Molecular y Celular, Facultad de CienciasUniversidad de ZaragozaZaragozaSpain